CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) announced today that it is awarding $1 million to Rhode Island Hospital at Brown University Health to develop a test to diagnose bacterial pneumonia from whole blood.
The hospital will use the funding to demonstrate proof of concept for a polymerase chain reaction (PCR) test that uses RNA sequencing to detect pneumonia caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae from whole blood drawn directly from the patient. The test would not require the blood to be cultured, which would allow for faster results.
While clinical diagnosis of pneumonia is typically based on patient symptoms and imaging, microbiologic diagnosis involves obtaining samples from patient airways. But because such samples are difficult to obtain, the pathogen often goes unidentified, and patients are typically treated with broad-spectrum antibiotics to cover a wide range of pathogens, which can increase the risk of resistance and poor outcomes.
"This innovative diagnostic approach holds the potential to improve access to testing for lower-respiratory-tract infections [LRTIs], including pneumonia, enabling clinicians to make faster, more informed decisions and reduce the use of broad-spectrum antibiotics," Erin Duffy, PhD, chief of research and development at CARB-X, said in a press release. "By supporting Rhode Island Hospital's work, CARB-X is learning whether alternative sample types in detecting LRTIs is promising for future product development."
Novel sample types for diagnosing LRTIs is one of the four distinct product themes for CARB-X's most recent funding round, launched in March 2024. Since its inception in 2016, CARB-X has funded 110 early-stage projects designed to prevent, diagnose, and treat antibiotic-resistant bacterial infections.